From DMSO to AI-Driven Rational Design: Borrowing from the Drug Discovery Paradigm to Unlock the "Vitrification Dilemma" in Organ Cryopreservation
Release time:
2026-08-14
Cryopreservation stands as a cornerstone technology for cell therapy, biobanking, and—looking ahead—organ transplantation. Yet since the discovery of glycerol in 1949 and dimethyl sulfoxide (DMSO) in 1959, innovation in permeating cryoprotective agents (CPAs) has remained virtually stagnant. By contrast, modern drug development has achieved systematic exploration of chemical space through high-throughput screening and artificial intelligence (AI). Recently, researchers from Duke University, the University of Toronto, and Insilico Medicine published a forward-looking paper in Advanced Science, proposing the introduction of the multi-parameter optimization (MPO) paradigm from drug discovery into CPA design—a disruptive approach that could reshape the field.
A "Common Language" Between Drug Discovery and CPA Design
Drug development demands a delicate balance among potency, safety, and ADME-T (absorption, distribution, metabolism, excretion, and toxicity). Similarly, an ideal CPA must simultaneously deliver high-efficiency ice-formation inhibition, low toxicity, favorable cell membrane permeability, and physicochemical stability suitable for scale-up. The research team systematically mapped conceptual equivalents between the two domains—for instance, a drug's "therapeutic index" corresponds to a CPA's "tissue-specific tolerance window," while combination drug therapy directly informs the design logic of multi-component CPA cocktails. They further proposed "Cryo's Rule of Five," establishing physicochemical benchmarks for CPA permeability and aqueous solubility analogous to Lipinski's Rule of Five.
From "Vitrification" to "Crystallization Inhibition": Vast Opportunities in Materials Science
Traditional CPAs primarily avoid ice-crystal damage through vitrification (forming an amorphous solid), yet vitrification is a metastable state highly prone to recrystallization upon rewarming. The article innovatively categorizes CPAs into three types: anti-dendritic agents (suppressing harmful dendritic ice crystals), semi-amorphous agents (forming low-damage ordered structures), and vitrifying agents. By modulating solute–water hydrogen-bonding networks, future CPAs might even permit the formation of "benign" microcrystals, thereby circumventing the need for ultra-high CPA concentrations.
AI Empowerment: Data Bottlenecks and Pathways Forward
AI-driven drug design relies on massive standardized datasets, but the CPA field faces a stark data scarcity—most studies report only qualitative outcomes such as "successful vitrification." To address this, the authors advocate establishing public CPA datasets spanning temperature, concentration, and exposure time, and adopting multi-fidelity modeling: using molecular dynamics simulations to generate synthetic data for model pre-training, followed by active learning to guide high-value experiments. Furthermore, physical innovations such as volumetric heating via magnetic nanoparticles could help resolve thermal gradient challenges in large-volume organ preservation.
By integrating the systematic optimization framework of drug discovery with a materials-science perspective, CPA design is evolving from empirical trial-and-error toward rational innovation. As "cryo-omics" data accumulate and AI tools mature, safer and more effective cryoprotectants and formulations are poised to emerge at an accelerated pace—paving the way for the long-term preservation of human cells, tissues, and ultimately whole organs.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
